Patent · US Active

Modulation of UBE3A-ATS expression

US10400243B2 · kind B2 · utility

2Cited by
43References
28Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 25, 2015
Grant dateSep 3, 2019
Priority date—
Expiry dateNov 25, 2035

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2310/3525
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Certain embodiments are directed to methods and compounds for inhibiting UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A). Such methods and compounds are useful for. Several embodiments provided herein relate to the discovery that antisense compounds targeting UBE3A-ATS induce paternal expression of UBE3A. Several embodiments are drawn to methods and compounds for inducing paternal expression of UBE3A using antisense compounds targeting UBE3A-ATS within a region of UBE3A-ATS that includes the sequence of the small nucleolar RNA (snoRNA), HBII-85 (also referred to as SNORD116).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.